

Contents

1. Introduction	1
2. Concepts and definitions	1
2.1 Changes in terminology and terms of reference of the Committee	1
2.2 Use of terms	4
2.2.1 Dependence	4
2.2.2 Withdrawal syndrome	5
2.2.3 Tolerance	5
2.2.4 Harmful use and abuse	6
2.2.5 Dependence-producing drug	6
3. Changes in the world situation in the last two decades	7
3.1 WHO activities in drug dependence	7
3.2 Patterns of use and responses to drug-related problems	8
3.2.1 Consumption of psychoactive drugs	8
3.2.2 Enforcement efforts	9
3.2.3 AIDS/HIV infection	10
3.2.4 The "combined approach"	10
3.3 Factors affecting drug use and drug-related problems	11
3.3.1 Transportation, migration and communication	11
3.3.2 Free markets, free trade, and their implications for public health	12
3.3.3 Some successes for regulation	13
3.3.4 The growth of community involvement	13
4. Drug-related problems and patterns of use	14
4.1 Types of drug-related problems	14
4.2 Indicators of drug-related problems	16
5. Approaches to prevention	18
5.1 Public health regulation	18
5.1.1 Forms of regulation for public health purposes	18
5.1.2 Regulation of traditional use of naturally occurring psychoactive drugs	19
5.1.3 Regulation and the rational use of medicinal psychoactive drugs	20
5.2 Educational approaches to prevention	21
5.3 Community approaches	21
5.4 Environmental approaches	22
5.5 Deterrence approaches	23
5.6 Public opinion	23
6. Treatment responses to harmful use of psychoactive substances	24
6.1 The importance of treatment	24
6.2 The need for a multiple and integrated treatment response	25
6.2.1 The need for a diverse response	25
6.2.2 Primary health care	25
6.2.3 General medical and psychiatric services	25
6.2.4 Specialized services	25
6.2.5 Treatment within the penal system	26
6.2.6 Treatment services in the community context	26
6.3 Health service planning	26
6.3.1 The need for planning	26
6.3.2 Planning in relation to the problems posed by different types of drugs	27

6.3.3	Professional training	27
6.3.4	Planning needs related to the emergence of HIV	27
6.3.5	Planning services in developing countries	27
6.4	What can be expected of treatment?	28
6.4.1	The essentials of the treatment process	28
6.4.2	The need to take a long-term view	28
6.4.3	Harm minimization	28
6.4.4	The development of treatment services	28
7.	Research and evaluation	29
8.	The need for an integrated national policy on psychoactive drugs	30
9.	Recommendations	31
9.1	Integration of approaches	31
9.2	Definitions and use of terms	32
9.3	Health promotion and the prevention of drug use and drug-related problems	32
9.4	Treatment services	32
9.5	Training	33
9.6	Regulatory control	34
9.7	Research	35
9.8	National policies and programmes	35
9.9	Human rights and ethical issues	36
10.	Pre-review of psychoactive substances	36
10.1	Review procedure	37
10.2	Pre-review of individual substances	37
10.2.1	Aminorex (INN)	37
10.2.2	Brotizolam (INN)	38
10.2.3	Coca leaf	38
10.2.4	Etryptamine (INN) or α -ethyltryptamine	39
10.2.5	Flunitrazepam (INN)	39
10.2.6	Mesocarb (INN)	39
10.2.7	Methcathinone	40
10.2.8	Tramadol (INN)	40
10.2.9	Triazolam (INN)	41
10.2.10	Zipeprol (INN)	41
	Acknowledgements	41
	References	42